Glucose Health, Inc. Appoints Strategic Investor Christopher J. Jemapete to Its Board of Directors

Rhea-AI Summary

Glucose Health (OTC: GLUC) appointed strategic investor Christopher J. Jemapete to its Board of Directors effective October 29, 2025. Mr. Jemapete, an early investor since 2017, holds a substantial equity stake and brings three decades of financial‑services experience from firms such as E.F. Hutton, Shearson Lehman Brothers, Fidelity, and ALPS Distributors.

He has participated in Private Placements since 2019 and helped raise over $2 million in capital. Management highlighted an established retail distribution footprint for GLUCODOWN and FIBER UP via Amazon and the two largest U.S. pharmacy chains, and emphasized the need for adequate capitalization to execute growth plans.

Positive

• Board addition: Strategic investor with 30 years' finance experience
• Insider alignment: Director holds a substantial equity position in GLUC
• Capital support: Participated in private placements raising over $2 million
• Retail distribution: Products carried on Amazon and two largest U.S. pharmacy chains

Negative

• Capital risk: Company needs adequate capitalization to execute strategic plan
• Execution dependent: Growth hinges on securing additional capital support

BENTONVILLE, Ark., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) today announced a further strengthening of its Board of Directors with the appointment of Christopher J. Jemapete, effective today. Mr. Jemapete was an early strategic investor in Glucose Health, Inc. beginning in 2017 and continues to maintain a substantial equity position in the company.

Mr. Jemapete brings three decades of experience in the financial services and securities industry to the Board of Directors of Glucose Health, Inc., having held senior roles with prominent Wall Street firms, including E.F. Hutton, Shearson Lehman Brothers, and Fidelity Investments. Mr. Jemapete concluded his professional career with a tenure at ALPS Distributors, Inc., located in Denver, Colorado, before his retirement in 2010.

Since retiring, Mr. Jemapete has dedicated his efforts to identifying and supporting investment opportunities in the micro-cap sector of the equity markets. Through his deep research methodology, he has developed a comprehensive understanding of the operational and financial challenges faced by emerging companies—particularly in areas related to capital formation, financing structures, and the execution of strategic growth initiatives.

As one of the earliest strategic investors in Glucose Health, Inc. Mr. Jemapete has participated in each of the Private Placements offered by Glucose Health, Inc. since 2019 and played an essential role in the successful raising of over $2 million in capital. His firm conviction in the mission of Glucose Health, Inc. —to deliver functional food and beverage products designed to address the growing public health challenges of obesity and diabetes—led to his decision today, to join the Company’s Board of Directors.

In outlining his priorities for the Company’s future, Mr. Jemapete remarked:

“The central challenge for Glucose Health, Inc. has always been, and continues to be, ensuring adequate capitalization to implement its strategic business plan fully. The Company has already established a robust retail distribution network for its flagship products, GLUCODOWN® and FIBER UP®, through major partners including Amazon and the two largest brick-and-mortar pharmacy chains in the United States. Our focus moving forward must be to build upon this foundation to drive meaningful revenue growth and enhance shareholder value. I am confident that, with sufficient capital support, the Company can successfully build upon this foundation and deliver exceptional returns for our shareholders.”

Mr. Jemapete holds a Bachelor of Science degree in Marketing from Fairfield University in Fairfield, Connecticut, and completed a two-year graduate program at Adelphi University in Garden City, New York, earning certification as a Certified Financial Planner.

Contact:
Investor Relations
info@glucosehealthinc.com
www.glucodown.com
www.fiberup.com
OTC: GLUC

FAQ

Who is Christopher J. Jemapete and why was he appointed to Glucose Health's board on October 29, 2025?

Mr. Jemapete is an early strategic investor since 2017 with 30 years' financial‑services experience who holds a substantial equity stake and joined the board to support capitalization and growth.

How much capital has Christopher J. Jemapete helped Glucose Health raise since 2019?

He participated in Private Placements and played a role in raising over $2 million in capital.

What are Glucose Health's flagship products and where are they sold as of October 29, 2025?

Flagship products are GLUCODOWN and FIBER UP, distributed through Amazon and the two largest U.S. brick‑and‑mortar pharmacy chains.

What priority did the new director identify for Glucose Health on joining the board?

He emphasized ensuring adequate capitalization to fully implement the company's strategic business plan and drive revenue growth.

Does Christopher J. Jemapete's appointment change shareholder alignment for GLUC (OTC: GLUC)?

Yes; as an early investor holding a substantial equity position, his board seat increases investor alignment between management and a significant shareholder.